{
  "id": 538739,
  "title": "Gland Pharma Share Price Surges 12% To Four-Year High After Strong Q1FY27 Results",
  "url": "https://urgent.news/2026/08/11/gland-pharma-share-price-surges-12-to-four-year-high-after-strong",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-11T06:19:07.000Z",
  "source": {
    "name": "Free Press Journal",
    "slug": "free-press-journal",
    "url": "https://www.freepressjournal.in/business/gland-pharma-share-price-surges-12-to-four-year-high-after-strong-q1fy27-results"
  },
  "original_language": "en",
  "account": null,
  "summary": "Gland Pharma's share price surged 12% to a four-year high of ₹2,989.25 after the pharmaceutical company reported strong Q1FY27 results. The company's profit after tax rose 47% year-on-year to ₹317 crore, while revenue from operations increased 19.6% to ₹1,800 crore. EBITDA rose 33% to ₹489 crore, and the EBITDA margin improved by 276 basis points to 27.2%. Gland Pharma's growth was driven by strong performance in the US and EU markets, despite subdued results in other key markets. The company plans to invest over ₹2,000 crore in capital expenditure over the next five years to expand capacity, with existing facilities operating at 80-90% utilisation. Analysts expect the company's long-term outlook to remain positive due to recent agreements, including a sterile API partnership with Neuland and a CDMO partnership with a global specialty pharmaceutical company.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}